Login / Signup

Risk of acute liver injury following the nirmatrelvir/ritonavir use.

Carlos King-Ho WongLoey Lung-Yi MakIvan Chi Ho AuWing Yiu ChengChing Hei SoKristy Tsz Kwan LauEric Ho Yin LauBenjamin John CowlingGabriel Matthew LeungMan Fung Yuen
Published in: Liver international : official journal of the International Association for the Study of the Liver (2023)
The risk of ALI associated with nirmatrelvir/ritonavir treatment for COVID-19 was elevated in the pre-exposure period, but not following nirmatrelvir/ritonavir initiation. ALI following nirmatrelvir/ritonavir treatment were mostly mild and less severe than ALI events in non-nirmatrelvir/ritonavir users.
Keyphrases
  • liver injury
  • drug induced
  • antiretroviral therapy
  • sars cov
  • respiratory failure
  • hepatitis b virus
  • replacement therapy
  • respiratory syndrome coronavirus